Matches in SemOpenAlex for { <https://semopenalex.org/work/W3113257430> ?p ?o ?g. }
- W3113257430 endingPage "1440" @default.
- W3113257430 startingPage "1433" @default.
- W3113257430 abstract "The differential risk of incident dementia associated with receiving various overactive bladder (OAB) drugs is unknown.To estimate the association of antimuscarinic OAB drug (exposure), compared with a β-3 agonist (mirabegron), and incident dementia.A population-based nested case-control study was conducted in patients treated with OAB medications in Ontario, Canada. A total of 11 392 patients aged ≥66 yr with a new diagnosis of dementia between 2010 and 2017, and 29 881 age- and sex-matched controls without dementia were included in the study.Receipt of an antimuscarinic OAB drug or receipt of mirabegron, within the previous 6-12 mo.Cases developed dementia and Alzheimer's disease. Controls were derived from the general population and matched to cases based on important baseline characteristics. Odds ratios (ORs) for incident dementia, adjusted for demographic and health-related characteristics, were determined.Patients receiving solifenacin (OR 1.24; 95% confidence interval 1.08-1.43) and darifenacin (OR 1.30; 95% CI 1.08-1.56) in the prior 6 mo had increased odds of incident dementia compared with those receiving mirabegron. In the 6 mo to 1 yr prior to diagnosis, receipt of solifenacin (OR 1.34; 95% CI 1.11-1.60), darifenacin (OR 1.49; 95% CI 1.19-1.86), tolterodine (OR 1.21; 95% CI 1.02-1.45), and fesoterodine (OR 1.39; 95% CI 1.14-1.71) was associated with increased odds of incident dementia compared with receipt of mirabegron. No effect was seen with oxybutynin or trospium. Limitations included misclassification of the outcome and residual confounding associated with the use of health administrative databases.Older adults receiving solifenacin and darifenacin in the 6 mo prior to diagnosis, and those receiving solifenacin, darifenacin, tolterodine, or fesoterodine in the year prior to diagnosis, have increased odds of incident dementia, compared with those receiving mirabegron. Oxybutynin and trospium were not associated with dementia, likely due to a protopathic bias. Careful drug selection is warranted when treating patients with OAB.In a large Canadian cohort of patients who developed dementia after starting an overactive bladder (OAB) medication, those taking some anticholinergic medications for OAB have an increased risk of dementia compared with those taking mirabegron." @default.
- W3113257430 created "2020-12-21" @default.
- W3113257430 creator A5018171722 @default.
- W3113257430 creator A5046304922 @default.
- W3113257430 creator A5047781154 @default.
- W3113257430 creator A5049307189 @default.
- W3113257430 creator A5053276850 @default.
- W3113257430 creator A5091477558 @default.
- W3113257430 date "2022-09-01" @default.
- W3113257430 modified "2023-10-07" @default.
- W3113257430 title "Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study" @default.
- W3113257430 cites W1720251821 @default.
- W3113257430 cites W1924589945 @default.
- W3113257430 cites W1967347194 @default.
- W3113257430 cites W1977832402 @default.
- W3113257430 cites W1981726399 @default.
- W3113257430 cites W1990263121 @default.
- W3113257430 cites W1999730861 @default.
- W3113257430 cites W2002743872 @default.
- W3113257430 cites W2005313412 @default.
- W3113257430 cites W2008545228 @default.
- W3113257430 cites W2044589919 @default.
- W3113257430 cites W2054058720 @default.
- W3113257430 cites W2058823385 @default.
- W3113257430 cites W2101254387 @default.
- W3113257430 cites W2141243043 @default.
- W3113257430 cites W2158894504 @default.
- W3113257430 cites W2168499550 @default.
- W3113257430 cites W2306793661 @default.
- W3113257430 cites W2484519907 @default.
- W3113257430 cites W2509531641 @default.
- W3113257430 cites W2529512212 @default.
- W3113257430 cites W2582524520 @default.
- W3113257430 cites W2587046244 @default.
- W3113257430 cites W2597711797 @default.
- W3113257430 cites W2790000579 @default.
- W3113257430 cites W2939971450 @default.
- W3113257430 cites W2984884245 @default.
- W3113257430 cites W3012700435 @default.
- W3113257430 cites W3135862631 @default.
- W3113257430 doi "https://doi.org/10.1016/j.euf.2021.10.009" @default.
- W3113257430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34742663" @default.
- W3113257430 hasPublicationYear "2022" @default.
- W3113257430 type Work @default.
- W3113257430 sameAs 3113257430 @default.
- W3113257430 citedByCount "3" @default.
- W3113257430 countsByYear W31132574302023 @default.
- W3113257430 crossrefType "journal-article" @default.
- W3113257430 hasAuthorship W3113257430A5018171722 @default.
- W3113257430 hasAuthorship W3113257430A5046304922 @default.
- W3113257430 hasAuthorship W3113257430A5047781154 @default.
- W3113257430 hasAuthorship W3113257430A5049307189 @default.
- W3113257430 hasAuthorship W3113257430A5053276850 @default.
- W3113257430 hasAuthorship W3113257430A5091477558 @default.
- W3113257430 hasBestOaLocation W31132574302 @default.
- W3113257430 hasConcept C126322002 @default.
- W3113257430 hasConcept C142724271 @default.
- W3113257430 hasConcept C156957248 @default.
- W3113257430 hasConcept C204787440 @default.
- W3113257430 hasConcept C2777844464 @default.
- W3113257430 hasConcept C2778164427 @default.
- W3113257430 hasConcept C2778941218 @default.
- W3113257430 hasConcept C2779134260 @default.
- W3113257430 hasConcept C2779483572 @default.
- W3113257430 hasConcept C2779502394 @default.
- W3113257430 hasConcept C2781020410 @default.
- W3113257430 hasConcept C2908647359 @default.
- W3113257430 hasConcept C44249647 @default.
- W3113257430 hasConcept C71924100 @default.
- W3113257430 hasConcept C99454951 @default.
- W3113257430 hasConceptScore W3113257430C126322002 @default.
- W3113257430 hasConceptScore W3113257430C142724271 @default.
- W3113257430 hasConceptScore W3113257430C156957248 @default.
- W3113257430 hasConceptScore W3113257430C204787440 @default.
- W3113257430 hasConceptScore W3113257430C2777844464 @default.
- W3113257430 hasConceptScore W3113257430C2778164427 @default.
- W3113257430 hasConceptScore W3113257430C2778941218 @default.
- W3113257430 hasConceptScore W3113257430C2779134260 @default.
- W3113257430 hasConceptScore W3113257430C2779483572 @default.
- W3113257430 hasConceptScore W3113257430C2779502394 @default.
- W3113257430 hasConceptScore W3113257430C2781020410 @default.
- W3113257430 hasConceptScore W3113257430C2908647359 @default.
- W3113257430 hasConceptScore W3113257430C44249647 @default.
- W3113257430 hasConceptScore W3113257430C71924100 @default.
- W3113257430 hasConceptScore W3113257430C99454951 @default.
- W3113257430 hasFunder F4320313712 @default.
- W3113257430 hasFunder F4320319966 @default.
- W3113257430 hasFunder F4320322015 @default.
- W3113257430 hasFunder F4320334506 @default.
- W3113257430 hasIssue "5" @default.
- W3113257430 hasLocation W31132574301 @default.
- W3113257430 hasLocation W31132574302 @default.
- W3113257430 hasLocation W31132574303 @default.
- W3113257430 hasOpenAccess W3113257430 @default.
- W3113257430 hasPrimaryLocation W31132574301 @default.
- W3113257430 hasRelatedWork W1994231517 @default.
- W3113257430 hasRelatedWork W2043977360 @default.
- W3113257430 hasRelatedWork W2072816571 @default.